Aprea Therapeutics, Inc. (APRE)
About Aprea Therapeutics, Inc.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$12.6M
- Total assets
- $15.9M
- Market cap
- $9.2M
- Operating margin
- -4631.1%
- Net margin
- -4409.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $285.8K
- Operating expenses
- $13.5M
- Operating income
- -$13.2M
- Income tax
- $0
- Net income
- -$12.6M
- EPS (basic)
- $-1.93
- EPS (diluted)
- $-1.93
Balance sheet
- Total assets
- $15.9M
- Current assets
- $15.6M
- Total liabilities
- $3.5M
- Current liabilities
- $2.8M
- Shareholders’ equity
- $12.4M
Cash flow
- Operating cash flow
- -$12.9M
- Investing cash flow
- $8.3M
- Financing cash flow
- $4.6M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $9.2M
- EPS (diluted)
- $-1.93
- Shares outstanding
- 14.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 3, 2019
Aprea Therapeutics, Inc. (APRE) Stock Price
- Reported a net loss of $12.6M.
- Trading 70% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aprea Therapeutics, Inc..
Write a review
News about Aprea Therapeutics, Inc.
News & sentiment via Polygon.io
Aprea Therapeutics, Inc.: frequently asked questions
Is Aprea Therapeutics, Inc. an American company?
Aprea Therapeutics, Inc. is a US-based company headquartered in Doylestown, Pennsylvania, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Aprea Therapeutics, Inc. headquartered?
Aprea Therapeutics, Inc. is headquartered in Doylestown, Pennsylvania, United States.
Is Aprea Therapeutics, Inc. publicly traded?
Yes — Aprea Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol APRE on the NASDAQ.
What does Aprea Therapeutics, Inc. do?
Aprea Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
